CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	12 Months Ended		56 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Revenue
Diagnostic testing service	$ 409,118	$ 475,402	$ 884,520
Product sales	223,440	6,440	231,380
Total revenue	632,558	481,842	1,115,900
Cost of revenue
Diagnostic testing service	105,764	35,745	141,509
Product sales	239,755	0	244,919
Total cost of revenue	345,519	35,745	386,428
Loss on obsolete inventory & LCM	149,946	29,884	271,856
Gross profit	137,093	416,213	457,616
Selling expenses	1,257,791	466,821	1,897,667
Research and development expenses	1,105,110	1,974,013	4,662,496
General and administrative expenses	8,558,835	3,044,409	14,381,171
Total operating expenses	10,921,736	5,485,243	20,941,334
Operating loss	(10,784,643)	(5,069,030)	(20,483,718)
Interest income	295	1,219	6,883
Interest expense	360	12,040	39,531
Net loss before Income taxes	(10,784,708)	(5,079,851)	(20,516,366)
Income taxes	0	0	248
Net loss	$ (10,784,708)	$ (5,079,851)	$ (20,516,614)
Loss per common share - basic and diluted (in dollars per share)	$ (0.70)	$ (0.41)	$ (2.14)
Weighted average shares outstanding, basic & diluted (in shares)	15,484,414	12,452,929	9,595,967